Page last updated: 2024-11-12
l 749345
Description
L 749345: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ertapenem sodium : The monosodium salt of ertapenem. It is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract. It is more stable to renal dehydropeptidase I tham imipenem, and so unlike imipenem, its use with cilastatin, which inhibits the enzyme, is not required. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (18)
| Synonym |
|---|
| ertapenem sodium |
| 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((3s,5s)-5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4r,5s,6s)- |
| l 749345 |
| 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-((5-(((3-carboxyphenyl)amino)carbonyl)-3-pyrrolidinyl)thio)-6-((1r)-1-hydroxyethyl)-4-methyl-7-oxo-, monosodium salt, (4r-(3(3s*,5s*),4alpha,5beta,6beta(r*)))- |
| invanz |
| mk 826 |
| 153773-82-1 |
| sodium (4r,5s,6s)-3-({(3s,5s)-5-[(m-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| sodium (4r,5s,6s)-3-({(3s,5s)-5-[(m-carboxyphenyl)carbamoyl]-3-pyrrolidinyl}thio)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| sodium (4r,5s,6s)-3-({(3s,5s)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidinium-3-yl}sulfanyl)-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| CHEBI:60070 , |
| ertapenem monosodium |
| 2t90ke67l0 , |
| mk 0826 |
| ertapenem sodium [usan] |
| unii-2t90ke67l0 |
| ertapenem monosodium (90per cent) |
| sodium;(4r,5s,6s)-3-[(3s,5s)-5-[(3-carboxylatophenyl)carbamoyl]pyrrolidin-1-ium-3-yl]sulfanyl-6-[(1r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| " The extended half-life at elimination phase of L-749,345 allows consideration of single daily dosing." | ( Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.
Gill, CJ; Hajdu, R; Kropp, H; Rosen, H; Sundelof, JG; Thompson, R, 1997) | 0.3 |
| "MK-826 (formerly L-749,345), is a potent 1-beta-methyl carbapenem with a long half-life and broad spectrum of activity." | ( In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345).
Gerckens, LS; Gill, CJ; Jackson, JJ; Kropp, H; Pelak, BA; Rosen, H; Sundelof, JG; Thompson, RK, 1998) | 0.3 |
| "L-749,345 is a new parenteral carbapenem with a very long half-life similar to that of ceftriaxone." | ( In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.
Cars, O; Löwdin, E; Odenholt, I, 1998) | 0.3 |
| " Clearance values based on unbound concentrations appeared independent of dose from 10 to 180 mg/kg, which is consistent with saturation of protein binding as the primary cause of the nonlinear pharmacokinetic behavior." | ( Dose-dependent plasma clearance of MK-826, a carbapenem antibiotic, arising from concentration-dependent plasma protein binding in rats and monkeys.
Bruhin, PJ; Lin, JH; Wong, BK, 1999) | 0.3 |
Compound-Compound Interactions
Roles (1)
| Role | Description |
|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| organic sodium salt | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (19)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (42.11) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.34
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.34 (24.57) | | Research Supply Index | 3.00 (2.92) | | Research Growth Index | 4.34 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (94.74%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |